Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection : Obstetrics & Gynecology

Secondary Logo

Journal Logo

Online College Publications

Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection

Author Information
Obstetrics & Gynecology 130(2):p e95-e101, August 2017. | DOI: 10.1097/AOG.0000000000002236
  • Free
  • Correction



The American College of Obstetricians and Gynecologists (ACOG) makes the following recommendations:

  • Intraamniotic infection, also referred to as chorioamnionitis, is an infection with resultant inflammation of any combination of the amniotic fluid, placenta, fetus, fetal membranes, or decidua.
  • Intraamniotic infection can be associated with acute neonatal morbidity, including neonatal pneumonia, meningitis, sepsis, and death, as well as long-term infant complications such as bronchopulmonary dysplasia and cerebral palsy.
  • For the purposes of this Committee Opinion, the diagnosis of suspected intraamniotic infection is made when the maternal temperature is greater than or equal to 39.0°C or when the maternal temperature is 38.0–38.9°C and one additional clinical risk factor is present.
  • For the purposes of this Committee Opinion, isolated maternal fever is defined as any maternal temperature between 38.0°C and 38.9°C with no additional risk factors present, and with or without persistent temperature elevation.
  • Administration of intrapartum antibiotics is recommended whenever an intraamniotic infection is suspected or confirmed. Antibiotics should be considered in the setting of isolated maternal fever unless a source other than intraamniotic infection is identified and documented.
  • Intraamniotic infection alone is rarely, if ever, an indication for cesarean delivery.
  • Regardless of institutional protocol, when obstetrician–gynecologists or other obstetric care providers diagnose an intraamniotic infection, or when other risk factors for early-onset neonatal sepsis are present in labor (eg, maternal fever, prolonged rupture of the membranes, or preterm birth), communication with the neonatal care team is essential to optimize neonatal evaluation and management.


Intraamniotic infection, also known as chorioamnio-nitis, is an infection with resultant inflammation of any combination of the amniotic fluid, placenta, fetus, fetal membranes, or decidua. Recently, some authors have suggested changing the name of this condition to “intra-amniotic infection and inflammation” to more accurately reflect the full spectrum of the disease process (1). This remains an evolving area, and for the purposes of this document, which focuses on the management of sus-pected or confirmed infection, the use of the term intra-amniotic infection is retained to identify this condition.

Intraamniotic infection often is polymicrobial in origin, commonly involves aerobic and anaerobic bacteria, and frequently originates from the vaginal flora (2). It predominantly occurs by ascending bacterial invasion from the lower genital tract to the typically sterile amniotic cavity. Intraamniotic infection also can occur, although rarely, after invasive procedures (eg, amniocentesis or chorionic villus sampling) or by a hematogenous route secondary to maternal systemic infection (eg, Listeria monocytogenes). However, most cases of intraamniotic infection detected and managed by obstetrician–gynecologists or other obstetric care providers will be noted among term patients in labor. Estimates suggest that approximately 2–5% of term deliveries are complicated by a clinically apparent intraamniotic infection (3, 4). More recent data suggest that the relative risk for intraamniotic infection and neonatal infection may increase after 40 completed weeks of gestation (3–5).

Intraamniotic infection can be associated with acute neonatal morbidity, including neonatal pneumonia, meningitis, sepsis, and death (3). The use of intrapartum antibiotic treatment given either in response to maternal group B streptococcal colonization or in response to evolving signs of intraamniotic infection during labor has been associated with a nearly 10-fold decrease in group B streptococcal-specific neonatal sepsis (6–8). Decreases in non-group B streptococcal neonatal infections also have been noted (9–11). The protective effect of maternal intra-partum antibiotic administration has been demonstrated in recent multivariate risk models of individual infant risk of neonatal sepsis (5, 12).

Intraamniotic infection can be associated with long-term complications for the infant, such as bronchopulmonary dysplasia and cerebral palsy (13, 14), potentially due to the effect of inflammation alone. A recent meta-analysis of 15 studies found a significantly higher relative risk of cerebral palsy among primarily premature infants exposed to either histologic chorioamnionitis (odds ratio [OR], 1.8; 95% CI, 1.17–2.89) or clinical chorioamnionitis (OR, 2.4; 95% CI, 1.52–3.84) (13). It is nonetheless important to acknowledge that the overall absolute risk of cerebral palsy remains quite low (approximately 2 per 1,000 live births) (15).

Maternal morbidity from intraamniotic infection also can be significant, and may include dysfunctional labor requiring increased intervention, postpartum uterine atony with hemorrhage, endometritis, peritonitis, sepsis, adult respiratory distress syndrome and, rarely, death (16, 17).

Obstetric risk factors for intraamniotic infection at term have been delineated, including low parity, multiple digital examinations, use of internal uterine and fetal monitors, meconium-stained amniotic fluid, and the presence of certain genital tract pathogens (eg, group B streptococcal infection and sexually transmitted infections) (3, 18–20). It should be recognized that many of these proposed risk factors also are associated with longer duration of labor and membrane rupture, and may not be independently associated with intraamniotic infection. For example, a recent retrospective investigation of more than 2,000 parturients specifically analyzed the number of cervical examinations performed during labor and found that women who developed an intrapartum fever had more digital cervical examinations than women who did not (21). However, this relationship was not significant after adjusting for spontaneous labor, the Bishop score, and rupture of membranes on admission.

Maternal intraamniotic infection is reasonably sensitive but lacks specificity with regard to the diagnosis of neonatal sepsis, particularly among preterm infants. Multivariate risk models for predicting neonatal sepsis among term and late-preterm infants have been developed based on objective data, including gestational age, duration of rupture of membranes, highest maternal intrapartum temperature, group B streptococcal colonization, and the type and timing of intrapartum antibiotic administration (5, 12, 22). These neonatal sepsis risk models do not affect maternal intrapartum management, but the use of maternal intrapartum data underscores the importance of communication with pediatric care providers as well as of appropriate maternal medical record documentation.

Presumptive Diagnosis of Intraamniotic Infection

The diagnosis of intraamniotic infection can be established objectively by amniotic fluid culture, or gram stain, or both and biochemical analysis, but for most women at term who are in labor the diagnosis is primarily made using clinical criteria. In a recent executive summary of proceedings from a joint workshop sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Society for Maternal–Fetal Medicine, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists, a panel of maternal and neonatal experts recommended separating intraamniotic infection into three different categories: 1) isolated maternal fever, 2) suspected intraamniotic infection, and 3) confirmed intraamniotic infection (1). The new definitions distinguish suspected and confirmed intraamniotic infection according to clinical and laboratory/pathologic findings, and provide standardized temperature criteria to diagnose intrapartum fever. According to the expert workshop executive summary, isolated maternal fever is defined as either a single oral temperature of 39°C or greater, or an oral temperature of 38–38.9°C that persists when the temperature is repeated after 30 minutes. Suspected intraamniotic infection is based on clinical criteria, which include maternal intrapartum fever and one or more of the following: maternal leukocytosis, purulent cervical drainage, or fetal tachycardia. Confirmed intraamniotic infection is based on a positive amniotic fluid test result (gram stain, glucose level, or culture results consistent with infection) or placental pathology demonstrating histologic evidence of placental infection or inflammation. In clinical practice, confirmed intraamniotic infection among women in labor at term will most commonly be made after delivery, based on histopathologic study of the placenta. Therefore, until better and less invasive intrapartum diagnostic tools become available, any practical distinction between suspected and confirmed intraamniotic infection will remain meaningful only in research settings and not for the obstetrician–gynecologist or other obstetric care provider managing a patient in labor. Diagnosis of confirmed histologic intraamniotic infection in the postpartum period does not alter postdelivery maternal treatment. Although the expert workshop executive summary included patients with temperature 39°C or greater with no other clinical risk factors present in the isolated maternal fever group, it is the opinion of the Committee on Obstetric Practice that absent an obvious alternative source, these patients be included in the suspected intraamniotic infection group. The American College of Obstetricians and Gynecologists’ recommendation optimizes sensitivity given that markedly elevated maternal temperatures are most likely due to infection, while transient lower temperature elevations may be due to infection or may be spurious, or related to noninfectious factors such as dehydration or epidural analgesia (23–25).

Management of Suspected or Confirmed Intraamniotic Infection

As demonstrated in a randomized clinical trial, intrapartum antibiotic therapy for intraamniotic infection decreases the rate of neonatal bacteremia, pneumonia, and sepsis (26). Multivariate models of neonatal sepsis risk demonstrate the positive effect of intrapartum antibiotics on the risk of culture-confirmed neonatal infection (5, 12). Intrapartum antibiotics also have been shown to decrease maternal febrile morbidity and length of hospital stay. Therefore, in the absence of any clearly documented overriding risks, administration of intrapartum antibiotics is recommended whenever intraamniotic infection is suspected or confirmed (26). Antipyretics should be administered in addition to antibiotics. Proper labor progression should be ensured, given the association between intraamniotic infection and dysfunctional labor progression (3, 16, 17, 27). In the absence of contraindications, augmentation of protracted labor in women with intraamniotic infection appears prudent. However, intraamniotic infection alone is not an indication for immediate delivery, and the route of delivery in most situations should be based on standard obstetric indications. Intraamniotic infection alone is rarely, if ever, an indication for cesarean delivery.

Management of Isolated Maternal Fever

For the purposes of this document, isolated maternal fever is defined as any temperature between 38°C and 38.9°C with no other clinical criteria indicating intraamniotic infection, and with or without persistent temperature elevation. In clinical care, an isolated maternal fever is a common scenario facing obstetrician–gynecologists or other obstetric care providers and, even absent additional criteria or persistent temperature elevation (as defined in the expert workshop executive summary), in practice clinicians often choose to treat for intraamniotic infection. Few data exist to guide appropriate management of women with isolated intrapartum fever in the absence of other clinical signs suggesting intraamniotic infection. Isolated intrapartum fever alone, whether due to infection or not, also has been associated with poor short-term and long-term neonatal outcomes (28–30). The exact mechanism of such an effect remains unclear, although fetal hyperthermia (and associated changes in metabolic rate) is hypothesized to potentiate the negative effects of tissue hypoxia. Prospective, randomized controlled studies are needed to better guide management of isolated intrapartum fever. Currently, given the potential benefits for the woman and newborn, antibiotics should be considered in the setting of isolated maternal fever unless a source other than intraamniotic infection is identified and documented. In some settings, this approach may result in increased awareness and diagnosis of intraamniotic infection, which will affect subsequent management of newborns. Whether or not a decision is made to initiate intrapartum antimicrobial therapy, the occurrence of maternal intrapartum fever should be communicated to the neonatal care team. Newer pediatric recommendations rely less on the clinical diagnosis of suspected intraamniotic infection, and more on consideration of a variety of risk factors and newborn clinical status to determine neonatal management.

Postdelivery Recommendations

Intrapartum antimicrobial agents administered for suspected or confirmed intraamniotic infection should not be continued automatically postpartum; rather, extension of antimicrobial therapy should be based on risk factors for postpartum endometritis (31–34). Data suggest that women who have vaginal deliveries are less likely to have endometritis and may not require postpartum antibiotics (32). For women undergoing cesarean deliveries, at least one additional dose of antimicrobial agents after delivery is recommended. However, the presence of other maternal risk factors such as bacteremia or persistent fever in the postpartum period may be used to guide continuation of antimicrobial therapy, duration of antimicrobial therapy, or both in vaginal and cesarean deliveries.

Common antibiotic choices for treatment of suspected intraamniotic infection are listed in Table 1. Obstetrician–gynecologists and other obstetric care providers also should consider consulting their local microbiology laboratory and infectious disease experts to ascertain whether there are alternative recommended regimens based on local antibiotic resistance patterns.

Table 1.:
Recommended Antibiotic Regimens for Treatment of Intraamniotic Infection

Neonatal Implications of an Intraamniotic Infection Diagnosis

The Centers for Disease Control and Prevention and the American Academy of Pediatrics provide guidelines for assessing risk of neonatal infection (7, 35–37). These guidelines recommend laboratory studies and empiric antibiotic therapy for all newborns delivered from women with a suspected or confirmed intraamni-otic infection. Currently such recommendations are being re-evaluated (1, 38). Recent data on the development of the neonatal microbiome and the role of early antibiotic exposures suggest that antibiotic therapy may not be entirely benign (39–46). Multivariate risk assessment and increased reliance on clinical observation may safely decrease the number of well-appearing term newborns treated empirically with antibiotics (5, 12, 22). In all cases, isolated maternal fever and suspected or confirmed intraamniotic infection should be communicated to neonatal caregivers at birth. Regardless of evolving national recommendations and local variations in approach, such infants always will require enhanced clinical surveillance for signs of developing infection.


Intraamniotic infection is a common condition noted among preterm and term parturients. Recognition of intrapartum intraamniotic infection and implementation of the treatment recommendations are essential steps that can effectively minimize morbidity and mortality for women and newborns. Timely maternal management together with notification of the neonatal health care providers will facilitate appropriate evaluation and empiric antibiotic treatment when indicated. Intraamniotic infection alone is rarely, if ever, an indication for cesarean delivery.


1. Higgins RD, Saade G, Polin RA, Grobman WA, Buhimschi IA, Watterberg K, et al. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol 2016;127:426–36.
2. Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis 1988;157:113–7.
3. Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993;36:795–808.
4. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol 2015;213:S29–52.
5. Escobar GJ, Puopolo KM, Wi S, Turk BJ, Kuzniewicz MW, Walsh EM, et al. Stratification of risk of early-onset sepsis in newborns >/= 34 weeks’ gestation. Pediatrics 2014;133:30–6.
6. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention [published erratum appears in MMWR Morb Mortal Wkly Rep 1996;45:679]. MMWR Recomm Rep 1996;45(RR-7):1–24.
7. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2010;59:1–36.
8. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs): emerging infections program network. Atlanta(GA): CDC; 2014. Available at:
9. Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale: 1928–2003. Pediatrics 2005;116:595–602.
10. Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010;125:e1031–8.
11. Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics 2016;138:e20162013.
12. Puopolo KM, Draper D, Wi S, Newman TB, Zupancic J, Lieberman E, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics 2011;128:e1155–63.
13. Shatrov JG, Birch SC, Lam LT, Quinlivan JA, McIntyre S, Mendz GL. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet Gynecol 2010;116:387–92.
14. Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. Am J Perinatol 2016;33:1076–8.
15. Oskoui M, Coutinho F, Dykeman J, Jette N, Pringsheim T. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis [published erratum appears in Dev Med Child Neurol 2016;58:316]. Dev Med Child Neurol 2013;55:509–19.
16. Rouse DJ, Landon M, Leveno KJ, Leindecker S, Varner MW, Caritis SN, et al. The Maternal-Fetal Medicine Units Cesarean registry: chorioamnionitis at term and its duration-relationship to outcomes. Am J Obstet Gynecol 2004;191:211–6.
17. Hauth JC, Gilstrap LC 3rd, Hankins GD, Connor KD. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985;66:59–62.
18. Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamniotic infection: a prospective epidemiologic study. Am J Obstet Gynecol 1989;161:562–6; discussion 566–8.
19. Newton ER, Prihoda TJ, Gibbs RS. Logistic regression analysis of risk factors for intra-amniotic infection. Obstet Gynecol 1989;73:571–5.
20. Tran SH, Caughey AB, Musci TJ. Meconium-stained amniotic fluid is associated with puerperal infections. Am J Obstet Gynecol 2003;189:746–50.
21. Cahill AG, Duffy CR, Odibo AO, Roehl KA, Zhao Q, Macones GA. Number of cervical examinations and risk of intrapartum maternal fever. Obstet Gynecol 2012;119: 1096–101.
22. Kuzniewicz MW, Puopolo KM, Fischer A, Walsh EM, Li S, Newman TB, et al. A quantitative, risk-based approach to the management of neonatal early-onset sepsis. JAMA Pediatr 2017;171:365–71.
23. Herbst A, Wolner-Hanssen P, Ingemarsson I. Risk factors for fever in labor. Obstet Gynecol 1995;86:790–4.
24. Yancey MK, Zhang J, Schwarz J, Dietrich CS 3rd, Klebanoff M. Labor epidural analgesia and intrapartum maternal hyperthermia. Obstet Gynecol 2001;98:763–70.
25. Riley LE, Celi AC, Onderdonk AB, Roberts DJ, Johnson LC, Tsen LC, et al. Association of epidural-related fever and noninfectious inflammation in term labor. Obstet Gynecol 2011;117:588–95.
26. Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS. A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection. Obstet Gynecol 1988;72:823–8.
27. Mark SP, Croughan-Minihane MS, Kilpatrick SJ. Chorio-amnionitis and uterine function. Obstet Gynecol 2000; 95:909–12.
28. Lieberman E, Lang J, Richardson DK, Frigoletto FD, Heffner LJ, Cohen A. Intrapartum maternal fever and neonatal outcome. Pediatrics 2000;105:8–13.
29. Impey L, Greenwood C, MacQuillan K, Reynolds M, Sheil O. Fever in labour and neonatal encephalopathy: a prospective cohort study. BJOG 2001;108:594–7.
30. Greenwell EA, Wyshak G, Ringer SA, Johnson LC, Rivkin MJ, Lieberman E. Intrapartum temperature elevation, epidural use, and adverse outcome in term infants. Pediatrics 2012;129:e447–54.
31. Black LP, Hinson L, Duff P. Limited course of antibiotic treatment for chorioamnionitis. Obstet Gynecol 2012;119:1102–5.
32. Edwards RK, Duff P. Single additional dose postpartum therapy for women with chorioamnionitis. Obstet Gynecol 2003;102:957–61.
33. Turnquest MA, How HY, Cook CR, O’Rourke TP, Cureton AC, Spinnato JA, et al. Chorioamnionitis: is continuation of antibiotic therapy necessary after cesarean section? Am J Obstet Gynecol 1998;179:1261–6.
34. Chapman SJ, Owen J. Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis. Am J Obstet Gynecol 1997;177:831–4.
35. Polin RA. Management of neonates with suspected or proven early-onset bacterial sepsis. Committee on Fetus and Newborn. Pediatrics 2012;129:1006–15.
36. Brady MT, Polin RA. Prevention and management of infants with suspected or proven neonatal sepsis. Pediatrics 2013;132:166–8.
37. Polin RA, Watterberg K, Benitz W, Eichenwald E. The conundrum of early-onset sepsis. Pediatrics 2014;133: 1122–3.
38. Benitz WE, Wynn JL, Polin RA. Reappraisal of guidelines for management of neonates with suspected early-onset sepsis. J Pediatr 2015;166:1070–4.
39. Madan JC, Farzan SF, Hibberd PL, Karagas MR. Normal neonatal microbiome variation in relation to environmental factors, infection and allergy. Curr Opin Pediatr 2012;24:753–9.
40. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009;123:58–66.
41. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011;159:392–7.
42. Ting JY, Synnes A, Roberts A, Deshpandey A, Dow K, Yoon EW, et al. Association between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr 2016;170:1181–7.
43. Mukhopadhyay S, Lieberman ES, Puopolo KM, Riley LE, Johnson LC. Effect of early-onset sepsis evaluations on in-hospital breastfeeding practices among asymptomatic term neonates. Hosp Pediatr 2015;5:203–10.
44. Alm B, Erdes L, Mollborg P, Pettersson R, Norvenius SG, Aberg N, et al. Neonatal antibiotic treatment is a risk factor for early wheezing. Pediatrics 2008;121:697–702.
45. Corvaglia L, Tonti G, Martini S, Aceti A, Mazzola G, Aloisio I, et al. Influence of intrapartum antibiotic prophylaxis for group B streptococcus on gut microbiota in the first month of life. J Pediatr Gastroenterol Nutr 2016;62:304–8.
46. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 2015;17:553–64.
© 2017 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.